Table 3.
Efficacy of subcutaneous tocilizumab in rheumatoid arthritis patients with inadequate response to DMARD
| TCZ dose | Week | ACR20% | ACR50–70%* | DAS28<2.6% | CDAI≤2.8% | Boolean % | HAQ-DI≥0.3% | Insufficient response % | |
|---|---|---|---|---|---|---|---|---|---|
| MATSURI12 | 81 mg q2w SC | 24 | 38 | 38–38 | 50 | NA | NA | NA | NA |
| 162 mg q2w SC | 24 | 83 | 83–50 | 83 | NA | NA | NA | NA | |
| 162 mg qw SC | 24 | 92 | 92–67 | 100 | NA | NA | NA | NA | |
| BREVACTA13,14 | 162 mg q2w SC | 24 | 61 | 40–20 | 32 | NA | NA | 58 | 0.9 |
| + DMARD | 48 | 62 | 45–26 | 45 | NA | NA | 62 | ||
| SUMMACTA15 | 162 mg qw SC | 24 | 68 | 46–24 | 37 | 14 | 11 | 65 | 1.7 |
| + DMARD | |||||||||
| MUSASHI16 | 162 mg q2w SC monotherapy | 24 | 79 | 64–37 | 50 | 16 | 16 | 57 | 1.7 |
| SUMMACTA and MUSASHI studies15,16 | 8 mg/kg IV q4w | 24 | 70 | 47–27 | 38 | 15 | 11 | 67 | 1.3 |
| 8 mg/kg IV q4w | 24 | 89 | 67–41 | 62 | 23 | 16 | 68 | 0.6 | |
Note:
The numbers listed first in this column refer to the percentage of the patients achieving the ACR50 response, and the numbers listed second in this column refer to the percentage of patients achieving the ACR70 response. By definition, all the patients achieving ACR70 achieve ACR50.
Abbreviations: ACR, American College of Rheumatology response rate; CDAI, clinical disease activity index; DAS, disease activity score; DMARD, disease-modifying antirheumatic drugs; HAQ-DI, health assessment questionnaire disability index; IV, intravenous; NA, not available; qw, every week; q2w, every two weeks; q4w, every four weeks; SC, subcutaneous; TCZ, tocilizumab.